SYNAPSEN - Étude de Cas 2023-2024

Innovative rare disease treatments

About SYNAPSEN - Étude de Cas 2023-2024

French company specializing in neuromuscular disorders, focusing on innovation and patient-centered values Developing a new treatment to launch in France

Key facts

Industry: Pharmaceutical Manufacturing
Company size: 1–10 employees
Headquarters: Orsay, Île-de-France, France
Founded: 2002
Revenue: $2.3M – $18.1MTamtam estimate
Website: instagram.com
LinkedIn: linkedin.com/company/synapsen-étude-de-cas-2023-2024

SYNAPSEN - Étude de Cas 2023-2024 at a glance

SYNAPSEN - Étude de Cas 2023-2024 is a B2B company in the Pharmaceutical Manufacturing industry, headquartered in Orsay, Île-de-France, France.

SYNAPSEN - Étude de Cas 2023-2024 was founded in 2002.

SYNAPSEN - Étude de Cas 2023-2024 has 1–10 employees.

SYNAPSEN - Étude de Cas 2023-2024's revenue is $2.3M – $18.1M (Tamtam estimate).

Frequently asked questions about SYNAPSEN - Étude de Cas 2023-2024

What is SYNAPSEN - Étude de Cas 2023-2024's revenue?

Tamtam estimates SYNAPSEN - Étude de Cas 2023-2024's annual revenue at $2.3M – $18.1M.

How many employees does SYNAPSEN - Étude de Cas 2023-2024 have?

SYNAPSEN - Étude de Cas 2023-2024 has 1–10 employees.

Where is SYNAPSEN - Étude de Cas 2023-2024 headquartered?

SYNAPSEN - Étude de Cas 2023-2024 is headquartered in Orsay, Île-de-France, France.

Selling to companies like SYNAPSEN - Étude de Cas 2023-2024?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies